IAN
VRTX icon

Integrated Advisors Network’s Vertex Pharmaceuticals VRTX Stock Holding History

Integrated Advisors Network’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$661K Sell
1,481
-693
-32% -$323K 0.03% 409
2025
Q4 		$986K Sell
2,174
-677
-24% -$292K 0.04% 348
2025
Q3 		$1.12M Buy
2,851
+771
+37% +$322K 0.05% 344
2025
Q2 		$926K Sell
2,080
-76
-4% -$35K 0.04% 372
2025
Q1 		$1.05M Sell
2,156
-924
-30% -$431K 0.05% 313
2024
Q4 		$1.24M Sell
3,080
-673
-18% -$312K 0.06% 273
2024
Q3 		$1.75M Buy
3,753
+381
+11% +$183K 0.08% 231
2024
Q2 		$1.58M Buy
3,372
+727
+27% +$316K 0.08% 229
2024
Q1 		$1.11M Buy
2,645
+683
+35% +$289K 0.06% 293
2023
Q4 		$798K Buy
1,962
+153
+8% +$56.5K 0.05% 325
2023
Q3 		$629K Buy
1,809
+9
+0.5% +$3.15K 0.04% 367
2023
Q2 		$633K Buy
1,800
+104
+6% +$35K 0.04% 375
2023
Q1 		$534K Buy
1,696
+46
+3% +$13.8K 0.03% 412
2022
Q4 		$476K Sell
1,650
-562
-25% -$171K 0.03% 426
2022
Q3 		$640K Sell
2,212
-52
-2% -$15K 0.04% 347
2022
Q2 		$638K Sell
2,264
-9
-0.4% -$2.41K 0.04% 366
2022
Q1 		$593K Buy
2,273
+310
+16% +$73.6K 0.03% 401
2021
Q4 		$431K Buy
1,963
+302
+18% +$58.7K 0.03% 443
2021
Q3 		$301K Buy
1,661
+208
+14% +$40.6K 0.02% 512
2021
Q2 		$293K Sell
1,453
-1,019
-41% -$213K 0.02% 484
2021
Q1 		$531K Buy
2,472
+441
+22% +$96.9K 0.05% 321
2020
Q4 		$480K Buy
2,031
+281
+16% +$64.5K 0.05% 288
2020
Q3 		$476K Buy
1,750
+266
+18% +$73.4K 0.06% 262
2020
Q2 		$430K Buy
1,484
+309
+26% +$83.8K 0.05% 278
2020
Q1 		$280K Buy
+1,175
New +$270K 0.05% 289

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Integrated Advisors Network's VRTX Position: Q1 2026 in Review

Integrated Advisors Network reduced its Vertex Pharmaceuticals (VRTX) stake by 32% in Q1 2026, selling an estimated $323K and leaving 1,481 shares worth $661K. The position accounts for 0.03% of the portfolio, ranked #409.

Integrated Advisors Network first reported a position in VRTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.75M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Integrated Advisors Network held 1,481 shares of Vertex Pharmaceuticals worth $661K as of Q1 2026.
  • Integrated Advisors Network sold 693 Vertex Pharmaceuticals shares in Q1 2026, an estimated $323K.
  • Vertex Pharmaceuticals made up 0.03% of Integrated Advisors Network's portfolio in Q1 2026, its #409 holding.
  • Integrated Advisors Network first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Integrated Advisors Network's Vertex Pharmaceuticals position peaked at $1.75M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Integrated Advisors Network's 13F filing for Q1 2026, filed 28 Apr 2026.